How Has the Lentiviral Vector Market Evolved Historically and What is its Current Size?
The lentiviral vector market has seen considerable growth due to a variety of factors.
• The market size for lentiviral vectors has witnessed robust expansion in the recent past. The market is projected to swell from $14.37 billion in 2024 to $16.62 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 15.7%.
Such growth during the historical timeframe can be traced back to factors such as the widespread presence of genetic disorders, increasing demand for gene delivery, growth in biotech and pharma sectors, investment in clinical trials, and regulatory approvals.
What is the Forecasted Market Size and CAGR for the Lentiviral Vector Market?
The lentiviral vector market is expected to maintain its strong growth trajectory in upcoming years.
• The market for lentiviral vectors is poised for significant expansion in the coming years. The market valuation is projected to reach $29.41 billion by 2029, increasing at a compound annual growth rate (CAGR) of 15.3%.
The anticipated surge during the forecast period is the result of various factors including the advancement of personalized medicine, innovation in gene editing, increased demand for rare disease treatments, the implementation of lentiviral vectors, funding in genomic medicine, and focus on manufacturing scalability. Key trends forecasted for this period encompass the expansion of research & development, incorporation in CAR-T cell treatment, the emergence of next-generation vectors, use in vaccine development, and the evolution of production technologies.
What Key Factors and Trends Are Driving The Growth Lentiviral Vector Market?
The surge in chronic illnesses is anticipated to spur the growth of the lentiviral vectors market. Chronic illnesses are typically slow-progressing, long-term health conditions that can often persist for a lifetime or several years. Increased aging populations, unhealthy lifestyles, urbanization, and environmental factors contribute to the rise in the prevalence of these diseases. Lentiviral vectors provide effective and adaptable tools for creating vaccines and treatment strategies for these chronic diseases, addressing unfulfilled medical needs and enhancing patient outcomes. For instance, the British Heart Foundation, a cardiovascular research charity based in the UK, reported in September 2024 that in the UK, around 7.6 million people live with heart and circulatory ailments, with the numbers divided almost equally between males and females. These diseases account for about 27% of all deaths in the UK, equating to over 170,000 deaths each year, or approximately 480 deaths daily. This equates to one death every three minutes. Consequently, the rising prevalence of chronic diseases is fuelling the expansion of the lentiviral vectors market.
What Are The Market Segments In The Lentiviral Vector Market?
The lentiviral vector market covered in this report is segmented –
1) By Product Type: Kits, Reagents And Consumables
2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications
3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes
Subsegments:
1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits
2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors
Pre-Book The Lentiviral Vector Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Lentiviral Vector Market?
Leading firms in the lentiviral vectors market are concentrating on the creation of LV vector production platforms like LentiSure, to amplify the effectiveness and stability of lentivirus vectors production for cell-based immuno-oncology treatments. LentiSure serves as a platform for LV vector creation, particularly employed in cell-based immuno-oncology therapies, and is engineered to augment production efficiency and resilience. For example, in May 2023, Yposkesi sk pharmteco, a company based in France that manufactures viral vectors, introduced LentiSure, a sophisticated platform created to boost the generation of lentiviral (LV) vectors, targeting the enhancement of lentivirus production's efficiency and reliability. This platform fills the growing need for sturdy and economically scalable viral-vector manufacturing technologies in cell and gene therapies. It provides uniform product quality with an average cell culture harvest titers at 10e7 IG/mL bioreactor volume, guaranteeing increased productivity and triumph for cell therapy developers.
Who Are the Key Players In The Lentiviral Vector Market?
Major companies operating in the lentiviral vector market are:
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi SA
• Bristol Myers Squibb Company
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc (GSK)
• Eli Lilly and Company
• Agilent Technologies Inc.
• Amgen Inc.
• Merck KGaA
• Lonza Group Ag
• Cytiva
• Charles River Laboratories
• Bio-Rad Laboratories Inc.
• Promega Corporation
• Takara Bio Inc.
• Sino Biological Inc.
• OriGene Technologies Inc.
• Applied Biological Materials Inc.
• Oxford Biomedica
• Sirion-Biotech GmbH
• Yposkesi
What Are The Regional Insights Into The Lentiviral Vector Market?
North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
